Cash-strapped Gritstone starts search for strategic alternatives as cancer vaccine data underwhelm

Gritstone bio has brought in bankers to explore “potential value-maximizing strategies” after its phase 2 colorectal cancer vaccine data fell short of the runaway success needed to transform its fortunes.